Impact of chronic obstructive pulmonary disease on short-term outcome in patients with ST-elevation myocardial infarction during COVID-19 pandemic: insights from the international multicenter ISACS-STEMI registry.
COPD
Mortality
STEMI
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
15 Aug 2022
15 Aug 2022
Historique:
received:
08
01
2022
accepted:
02
05
2022
entrez:
15
8
2022
pubmed:
16
8
2022
medline:
18
8
2022
Statut:
epublish
Résumé
Chronic obstructive pulmonary disease (COPD) is projected to become the third cause of mortality worldwide. COPD shares several pathophysiological mechanisms with cardiovascular disease, especially atherosclerosis. However, no definite answers are available on the prognostic role of COPD in the setting of ST elevation myocardial infarction (STEMI), especially during COVID-19 pandemic, among patients undergoing primary angioplasty, that is therefore the aim of the current study. In the ISACS-STEMI COVID-19 registry we included retrospectively patients with STEMI treated with primary percutaneous coronary intervention (PCI) between March and June of 2019 and 2020 from 109 high-volume primary PCI centers in 4 continents. A total of 15,686 patients were included in this analysis. Of them, 810 (5.2%) subjects had a COPD diagnosis. They were more often elderly and with a more pronounced cardiovascular risk profile. No preminent procedural dissimilarities were noticed except for a lower proportion of dual antiplatelet therapy at discharge among COPD patients (98.9% vs. 98.1%, P = 0.038). With regards to short-term fatal outcomes, both in-hospital and 30-days mortality occurred more frequently among COPD patients, similarly in pre-COVID-19 and COVID-19 era. However, after adjustment for main baseline differences, COPD did not result as independent predictor for in-hospital death (adjusted OR [95% CI] = 0.913[0.658-1.266], P = 0.585) nor for 30-days mortality (adjusted OR [95% CI] = 0.850 [0.620-1.164], P = 0.310). No significant differences were detected in terms of SARS-CoV-2 positivity between the two groups. This is one of the largest studies investigating characteristics and outcome of COPD patients with STEMI undergoing primary angioplasty, especially during COVID pandemic. COPD was associated with significantly higher rates of in-hospital and 30-days mortality. However, this association disappeared after adjustment for baseline characteristics. Furthermore, COPD did not significantly affect SARS-CoV-2 positivity. NCT04412655 (2nd June 2020).
Sections du résumé
BACKGROUND
BACKGROUND
Chronic obstructive pulmonary disease (COPD) is projected to become the third cause of mortality worldwide. COPD shares several pathophysiological mechanisms with cardiovascular disease, especially atherosclerosis. However, no definite answers are available on the prognostic role of COPD in the setting of ST elevation myocardial infarction (STEMI), especially during COVID-19 pandemic, among patients undergoing primary angioplasty, that is therefore the aim of the current study.
METHODS
METHODS
In the ISACS-STEMI COVID-19 registry we included retrospectively patients with STEMI treated with primary percutaneous coronary intervention (PCI) between March and June of 2019 and 2020 from 109 high-volume primary PCI centers in 4 continents.
RESULTS
RESULTS
A total of 15,686 patients were included in this analysis. Of them, 810 (5.2%) subjects had a COPD diagnosis. They were more often elderly and with a more pronounced cardiovascular risk profile. No preminent procedural dissimilarities were noticed except for a lower proportion of dual antiplatelet therapy at discharge among COPD patients (98.9% vs. 98.1%, P = 0.038). With regards to short-term fatal outcomes, both in-hospital and 30-days mortality occurred more frequently among COPD patients, similarly in pre-COVID-19 and COVID-19 era. However, after adjustment for main baseline differences, COPD did not result as independent predictor for in-hospital death (adjusted OR [95% CI] = 0.913[0.658-1.266], P = 0.585) nor for 30-days mortality (adjusted OR [95% CI] = 0.850 [0.620-1.164], P = 0.310). No significant differences were detected in terms of SARS-CoV-2 positivity between the two groups.
CONCLUSION
CONCLUSIONS
This is one of the largest studies investigating characteristics and outcome of COPD patients with STEMI undergoing primary angioplasty, especially during COVID pandemic. COPD was associated with significantly higher rates of in-hospital and 30-days mortality. However, this association disappeared after adjustment for baseline characteristics. Furthermore, COPD did not significantly affect SARS-CoV-2 positivity.
TRIAL REGISTRATION NUMBER
BACKGROUND
NCT04412655 (2nd June 2020).
Identifiants
pubmed: 35971173
doi: 10.1186/s12931-022-02128-0
pii: 10.1186/s12931-022-02128-0
pmc: PMC9376902
doi:
Banques de données
ClinicalTrials.gov
['NCT04412655']
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
207Informations de copyright
© 2022. The Author(s).
Références
Am J Respir Crit Care Med. 2011 Mar 15;183(6):734-42
pubmed: 20889904
Chest. 2012 Jun;141(6):1441-1448
pubmed: 22207679
Clin Cardiol. 2010 Apr;33(4):228-35
pubmed: 20394044
Ann Epidemiol. 2006 Jan;16(1):63-70
pubmed: 16039877
Allergy. 2019 Jul;74(7):1249-1256
pubmed: 30834543
Eur Respir J. 2019 May 18;53(5):
pubmed: 30846476
Arch Intern Med. 2012 Apr 23;172(8):611-21; discussion 621-2
pubmed: 22529227
Circulation. 2004 Mar 16;109(10):1223-5
pubmed: 15007008
Eur J Prev Cardiol. 2013 Jun;20(3):392-8
pubmed: 22023803
J Am Heart Assoc. 2017 Mar 15;6(3):
pubmed: 28298371
Thorax. 2009 Feb;64(2):144-9
pubmed: 18852155
Respir Med. 2020 Sep;171:106098
pubmed: 32777683
Thromb Haemost. 2000 Aug;84(2):210-5
pubmed: 10959691
Circulation. 2003 Mar 25;107(11):1514-9
pubmed: 12654609
Lancet Respir Med. 2021 Aug;9(8):909-923
pubmed: 33812494
EClinicalMedicine. 2021 Mar;33:100789
pubmed: 33758801
Int J Cardiol. 2013 Jul 1;166(3):606-12
pubmed: 22284272
Eur Heart J. 2018 Jan 7;39(2):119-177
pubmed: 28886621
Int J Cardiol. 2013 Oct 3;168(3):2070-81
pubmed: 23490083
Int J Cardiol. 2017 Sep 15;243:437-442
pubmed: 28506549
Multidiscip Respir Med. 2013 Sep 03;8(1):58
pubmed: 24004921
Chest. 2015 Jul;148(1):138-150
pubmed: 25675282
Lancet Respir Med. 2020 Jun;8(6):e50-e51
pubmed: 32411576
Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(4):222-230
pubmed: 31876907
Eur J Intern Med. 2018 Jan;47:82-86
pubmed: 28821412
Eur Respir Rev. 2020 Jun 23;29(156):
pubmed: 32581139
Int J Chron Obstruct Pulmon Dis. 2015 Nov 11;10:2459-67
pubmed: 26648708
COPD. 2005 Mar;2(1):35-41
pubmed: 17136959
Heart. 2015 Jul;101(14):1103-10
pubmed: 25765553
Cardiovasc Diabetol. 2020 Dec 18;19(1):215
pubmed: 33339541
Open Heart. 2014 Feb 03;1(1):e000002
pubmed: 25332773
Int J Cardiol. 2015 Jul 15;191:187-93
pubmed: 25965630
Am Heart J. 2013 Jan;165(1):43-9
pubmed: 23237132
Intern Med. 2002 Mar;41(3):181-5
pubmed: 11929177
Am J Cardiol. 2010 Aug 1;106(3):305-9
pubmed: 20643237
J Am Coll Cardiol. 2020 Nov 17;76(20):2321-2330
pubmed: 33183506
Biol Proced Online. 2020 Aug 4;22:19
pubmed: 32774178
COPD. 2015;12(5):560-7
pubmed: 25775224
J Am Coll Cardiol. 2019 May 7;73(17):2166-2177
pubmed: 30846341